Surveying the Proteome-Wide Landscape of Mitoxantrone and Examining Drug Sensitivity in BRCA1-Deficient Ovarian Cancer Using Quantitative Proteomics

<b>Background</b>: Mitoxantrone (MX) is regularly used to treat several cancers. Despite its long history in the clinic, recent studies continue to unveil novel protein targets. These targets may contribute to the cytotoxic effects of the drug, as well as potential non-canonical antitumor activity....

Cijeli opis

Bibliografski detalji

Glavni autori:	Savanna Wallin, Sneha Pandithar, Sarbjit Singh, Siddhartha Kumar, Amarnath Natarajan, Gloria E. O. Borgstahl, Nicholas Woods
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2025-11-01
Serija:	Proteomes
Teme:	mitoxantrone homologous recombination-deficiency ovarian cancer BRCA1 DNA repair proteomics
Online pristup:	https://www.mdpi.com/2227-7382/13/4/61
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!